Business Description
NovaBay Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US66987P3001
Description
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | -0.16 | |||||
| Debt-to-Equity | -3.26 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -69.36 | |||||
| Beneish M-Score | -6.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -29 | |||||
| 3-Year EBITDA Growth Rate | 43.3 | |||||
| 3-Year EPS without NRI Growth Rate | 22 | |||||
| 3-Year FCF Growth Rate | 40.4 | |||||
| 3-Year Book Growth Rate | -77.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 82.98 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.23 | |||||
| 9-Day RSI | 41.61 | |||||
| 14-Day RSI | 45.37 | |||||
| 6-1 Month Momentum % | -73.67 | |||||
| 12-1 Month Momentum % | -87.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | |||||
| Quick Ratio | 0.43 | |||||
| Cash Ratio | 0.21 | |||||
| Days Inventory | 166.87 | |||||
| Days Sales Outstanding | 33.87 | |||||
| Days Payable | 86.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -111.1 | |||||
| Shareholder Yield % | -7.04 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.55 | |||||
| Operating Margin % | -37.74 | |||||
| Net Margin % | -88.7 | |||||
| FCF Margin % | -28.26 | |||||
| ROE % | -288.89 | |||||
| ROA % | -113.02 | |||||
| ROIC % | -78.75 | |||||
| 3-Year ROIIC % | 61.58 | |||||
| ROC (Joel Greenblatt) % | -226.35 | |||||
| ROCE % | -118.41 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.02 | |||||
| EV-to-EBIT | -0.8 | |||||
| EV-to-EBITDA | -0.83 | |||||
| EV-to-Forward-EBITDA | -1.32 | |||||
| EV-to-Revenue | 0.39 | |||||
| EV-to-Forward-Revenue | 0.46 | |||||
| EV-to-FCF | -1.37 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -125 | |||||
| FCF Yield % | -100.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovaBay Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 11.128 | ||
| EPS (TTM) (€) | -43.168 | ||
| Beta | 0 | ||
| Volatility % | 60.74 | ||
| 14-Day RSI | 45.37 | ||
| 14-Day ATR (€) | 0.499867 | ||
| 20-Day SMA (€) | 3.398499 | ||
| 12-1 Month Momentum % | -87.91 | ||
| 52-Week Range (€) | 2.187499 - 26.249999 | ||
| Shares Outstanding (Mil) | 1.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovaBay Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovaBay Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NovaBay Pharmaceuticals Inc Frequently Asked Questions
What is NovaBay Pharmaceuticals Inc(STU:B9P0)'s stock price today?
The current price of STU:B9P0 is €2.99. The 52 week high of STU:B9P0 is €26.25 and 52 week low is €2.19.
When is next earnings date of NovaBay Pharmaceuticals Inc(STU:B9P0)?
The next earnings date of NovaBay Pharmaceuticals Inc(STU:B9P0) is .
Does NovaBay Pharmaceuticals Inc(STU:B9P0) pay dividends? If so, how much?
NovaBay Pharmaceuticals Inc(STU:B9P0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers